新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 产品 » Novaliq公司治疗干眼病新药临床一期数据良好

Novaliq公司治疗干眼病新药临床一期数据良好

来源:生物谷 2014-09-27 11:50

2014年9月27日讯 /生物谷BIOON/ --著名眼部疾病药物生产商Novaliq生物技术公司最近宣布公司开发的环孢菌素眼药水CyclASol在治疗干眼病的临床一期研究中取得了良好的成绩。公司表示CyclASol眼药水采用了公司独有的半氟烷载药系统进行输送,临床一期研究显示,18名参与研究的干眼病患者的病情都得到了显着缓解,同时这些患者并没有产生与药物相关的副作用,如疲劳、红眼等状况。研究人员表示采用这一载药系统能够避免环孢菌素的一些常见副作用。同时也解决了这种药物成分不宜溶解的难题。

公司首席科学官Dieter Scherer表示,目前市面上一直缺少有效的治疗干眼病的药物,而环孢菌素作为一种治疗这种疾病非常有效的药物,其应用一直受到其难溶性和引发的一些副作用的限制。CyclAsol有望成功克服这一难题。

Novaliq公司一直致力于眼部疾病的药物研发,去年公司获得了Dietmar Hopp's Dievini Hopp BioTech Holding投资公司1800万美元的投资。

干眼症是指任何原因造成的泪液质或量异常或动力学异常,导致泪膜稳定性下降,并伴有眼部不适和(或)眼表组织病变特征的多种疾病的总称。又称角结膜干燥症。常见之症状包括眼睛干涩、容易疲倦、眼痒、有异物感、痛灼热感、分泌物黏稠、怕风、畏光、对外界刺激很敏感;有时眼睛太干,基本泪液不足,反而刺激反射性泪液分泌,而造成常常流泪;较严重者眼睛会红肿、充血、角质化、角膜上皮破皮而有丝状物黏附,许多人认为这种疾病只是一种小毛病,但是如果不及时治疗会给眼睛造成很大负担并影响视力。(生物谷Bioon.com)

本文系生物谷原创编译整理,欢迎转载!转载请注明来源并附原文链接 谢谢!

详细英文报道:

Eye drug delivery outfit Novaliq touted a positive Phase I for its cyclosporin eye drops designed to treat dry eye disease. Novaliq's semifluorinated alkane technology allows for a clear solution of cyclosporin, which is poorly soluble in water, thus making for a more effective eye drop that doesn't impair vision, the company says.

In the early-stage study of its CyclASol eye drops, the 18 patients involved showed no drug-related symptoms, according to a release, and no reported discomfort, including "dryness, grittiness, burning, stinging, tiredness, blurred or foggy vision, redness, watery eyes, eye mucus or crusting." These are some of the side effects often associated with cyclosporin when administered as an emulsion as opposed to a dissolved solution made possible with the semifluorinated alkanes.

"For patients with dry eye disease, there are few approved drug options available," Chief Scientific Officer Dieter Scherer said in a statement. "Cyclosporin is a well-accepted active drug substance for this disease, although current formulations come with several limitations including side effects and limited patient acceptance due to cyclosporin's poor solubility."

Novaliq brought in an $18 million round last year from entrepreneur Dietmar Hopp's Dievini Hopp BioTech Holding, which also contributed the rest of a total $35 million in financing. Most of that latest round went into spurring CyclASol into its clinical trial.

Also making use of the alkane platform is Novaliq's over-the-counter NovaTears, which secured a CE mark last summer.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库